Asian patients are rarely represented in large TAVR trials, the authors wrote, so they focused on nearly 1,200 patients from South Korea to provide a fresh perspective. 

A hybrid approach may increase the risk of certain adverse events, according to a new meta-analysis focused on long-term outcomes. 

Abbott's HeartMate 3 LVAD is the only FDA-approved device of its kind currently available in the United States. Should reports of adverse events worry cardiologists? Or are they to be expected when treating such a vulnerable patient population?

While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.

AI-based prediction models have shown significant promise, but many are still flawed in a way that limits their value. 

Prosecutors successfully argued that the patient would not have died if clinicians had ordered a routine CT exam. 

Hospitals should be making every effort to help sonographers deliver better, more accurate echocardiograms and improve the diagnosis of severe aortic stenosis. If you take care of your sonographers, your sonographers will take care of you. 

Valve-in-valve TAVR outperforms redo SAVR for the first six months after treatment, according to a new meta-analysis published in the American Journal of Cardiology. Then, however, things begin to shift.